Visual of a brain
Biotech

Roche ends 2 Huntington’s programs, including Ionis ASO

Both drugs are antisense oligonucleotides targeting the huntingtin gene, which causes Huntington’s when a mutation leads to its expansion over time.
Darren Incorvaia Jul 9, 2026 2:40pm
GSK ESMO

GSK sees phase 3 win for Hansoh-partnered ADC as justifying hype

Jul 10, 2026 8:39am
ArticlePrimaryImagejpg

Can We Outrun Cancer's Evolution? Why We Need a New Approach

Brought to you by BrYet US, Inc.
Hand with tweezers editing DNA

ARPA-H awards up to $160M for custom genetic medicines

Jul 10, 2026 4:00am
Closeup of blue eye on black background

Bausch + Lomb gives up on glaucoma eye drop hopeful after fail

Jul 10, 2026 7:31am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Idorsia locks in new CEO after shakeup—Chutes & Ladders

Jul 10, 2026 8:30am
More News

Fierce Biotech Fundraising Tracker '26: MindRank funds GLP-1

Jul 10, 2026 5:00am

Illumina taps new commercial, legal chiefs

Jul 9, 2026 1:26pm

Fate’s CAR-T prospect shows early promise in systemic sclerosis

Jul 9, 2026 10:24am

Biotech revenue plans ‘won’t look as sunny’ after Trump tax bill

Jul 9, 2026 9:28am